6 Cedarbrook Drive, Cranbury, NJ 08512, USA cfpc.jstar@jstar-research.com

Category : 2022 Abstracts

Enabling Technologies for Tox/FIH Formulation

By Dr. San Kiang, J-Star Research / Porton The business goal of most CMC development is to reach FIH as fast as possible. However, before IND or Phase 1,...

Novel analytical methods and insights into Amorphous Solid Dispersions

By Dr. Simon Bates, Rigaku Americas Corp X-ray powder diffraction has been the gold standard for solid state pharmaceutical analysis for quite some time. However, when it comes to...

Digitally Enabled Workflows: Accelerating the Molecule to Medicine Journey

By Dr. Bob Docherty, Pfizer The focus would be on solid form screen & selection, crystallization process development, pre-formulation evaluations, particle engineering and projecting the API attributes to drug...

Reducing or Managing Complexity- New realities with emerging chemical space for small molecule developability

By Dr. Ahmad Sheikh, AbbVie While new chemical entities represent majority of the drugs approved in the last five years, the diversity and complexity of these molecules continue to...

Control, is it achievable in amorphous or poorly crystalline peptide isolations?

By Dr. Jeremy M. Merritt, Eli Lilly and Co. Abstract: pending

RSS
Follow by Email
LinkedIn
Share